Infectocure 125 ml/5 ml suspension 60 ml
0£
View analogsInfectocure 125mg/5ml, 60ml suspension is a children's antibiotic containing clarithromycin. It is used for respiratory tract, ear, throat and skin infections in children.
Form of Release: Suspension
Product Brand: EGPI
Product Categories: Antibiotics • Broad spectrum antibiotics
Infectocure 125mg/5ml suspension 60 ml
Composition:
Clarithromycin (Clarithromycin) - 125 mg in 5 ml of ready-made suspension
Dosage form: Powder for preparation of suspension for oral use
Class: Antibiotic, second-generation macrolide
Pharmacological properties:
Clarithromycin acts bacteriostatically (stops bacterial growth), and in high doses - bactericidal. It disrupts protein synthesis in bacterial cells, blocking their reproduction.
Effective against:
Streptococcus pyogenes
Haemophilus influenzae
Staphylococcus aureus
Mycoplasma pneumoniae
Chlamydia pneumoniae
Helicobacter pylori
Legionella pneumophila
Also exhibits activity against atypical pathogens of respiratory infections and mycobacteria in patients with immunodeficiency.
Indications for use:
Respiratory tract infections:
bronchitis, pneumonia, sinusitis, pharyngitis, tonsillitis
Otitis (inflammation of the middle ear)
Skin and soft tissue infections
Helicobacter pylori infection of the stomach (as part of complex therapy)
Mycobacterial infections (in immunocompromised patients)
Method of administration and dosage:
The dosage may vary depending on age, weight and severity of the infection. Always follow the dosage prescribed by your doctor. Do not exceed the recommended dosage.
Tags, Keywords:
- children's antibiotic
- respiratory tract infections
- skin infections
- upper respiratory tract infections
- bronchitis
- bronchitis
- bronchitis
- pneumonia
- sinusitis
- sinusitis
- sinusitis
- Sinusitis treatment
- pharyngitis
- pharyngitis
- pharyngitis
- tonsilitis
- tonsillitis in children
- tonsillitis
- Tonsillitis
- otitis
- otitis media
Active Ingredients:
No comments yet. Be the first to write one.
Your comment will be published after moderation.
You’ll receive a notification to your email when someone replies.
Русский
English
عربي

